Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Targeting Casein Kinase 1 (CK1) in Hematological Cancers

P. Janovská, E. Normant, H. Miskin, V. Bryja

. 2020 ; 21 (23) : . [pub] 20201127

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011837

Grantová podpora
GX19-28347X Czech Science Foundation
CZ.02.1.01/0.0/0.0/16_025/0007381 Ministry of Education, Youth and Sports of the CR

The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven CK1 isoforms identified in humans. The most important substrates of CK1 kinases are proteins that act in the regulatory nodes essential for tumorigenesis of hematological malignancies. Among those, the most important are the functions of CK1s in the regulation of Wnt pathways, cell proliferation, apoptosis and autophagy. In this review we summarize the recent developments in the understanding of biology and therapeutic potential of the inhibition of CK1 isoforms in the pathogenesis of chronic lymphocytic leukemia (CLL), other non-Hodgkin lymphomas (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and multiple myeloma (MM). CK1δ/ε inhibitors block CLL development in preclinical models via inhibition of WNT-5A/ROR1-driven non-canonical Wnt pathway. While no selective CK1 inhibitors have reached clinical stage to date, one dual PI3Kδ and CK1ε inhibitor, umbralisib, is currently in clinical trials for CLL and NHL patients. In MDS, AML and MM, inhibition of CK1α, acting via activation of p53 pathway, showed promising preclinical activities and the first CK1α inhibitor has now entered the clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011837
003      
CZ-PrNML
005      
20210507102803.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21239026 $2 doi
035    __
$a (PubMed)33261128
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Janovská, Pavlína $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500 Brno, Czech Republic
245    10
$a Targeting Casein Kinase 1 (CK1) in Hematological Cancers / $c P. Janovská, E. Normant, H. Miskin, V. Bryja
520    9_
$a The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven CK1 isoforms identified in humans. The most important substrates of CK1 kinases are proteins that act in the regulatory nodes essential for tumorigenesis of hematological malignancies. Among those, the most important are the functions of CK1s in the regulation of Wnt pathways, cell proliferation, apoptosis and autophagy. In this review we summarize the recent developments in the understanding of biology and therapeutic potential of the inhibition of CK1 isoforms in the pathogenesis of chronic lymphocytic leukemia (CLL), other non-Hodgkin lymphomas (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and multiple myeloma (MM). CK1δ/ε inhibitors block CLL development in preclinical models via inhibition of WNT-5A/ROR1-driven non-canonical Wnt pathway. While no selective CK1 inhibitors have reached clinical stage to date, one dual PI3Kδ and CK1ε inhibitor, umbralisib, is currently in clinical trials for CLL and NHL patients. In MDS, AML and MM, inhibition of CK1α, acting via activation of p53 pathway, showed promising preclinical activities and the first CK1α inhibitor has now entered the clinical trials.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a kaseinkinasa I $x antagonisté a inhibitory $x chemie $x metabolismus $7 D047389
650    _2
$a hematologické nádory $x farmakoterapie $x enzymologie $x patologie $7 D019337
650    _2
$a lidé $7 D006801
650    12
$a cílená molekulární terapie $7 D058990
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $x patologie $7 D014411
650    _2
$a signální dráha Wnt $7 D060449
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Normant, Emmanuel $u TG Therapeutics, New York, NY 10014, USA
700    1_
$a Miskin, Hari $u TG Therapeutics, New York, NY 10014, USA
700    1_
$a Bryja, Vítězslav $u Department of Experimental Biology, Faculty of Science, Masaryk University, 62500 Brno, Czech Republic $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, 61265 Brno, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 23 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33261128 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102803 $b ABA008
999    __
$a ok $b bmc $g 1650265 $s 1132216
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 23 $e 20201127 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a GX19-28347X $p Czech Science Foundation
GRA    __
$a CZ.02.1.01/0.0/0.0/16_025/0007381 $p Ministry of Education, Youth and Sports of the CR
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace